Minerva Neurosciences (NERV) Q3 2024 earnings summary

Executive summary

• Net income for Q3 2024 was $22.5 million, reversing a net loss of $7.8 million in Q3 2023, primarily due to a $26.6 million gain from the adjustment of the royalty obligation.

• The FDA issued a Complete Response Letter (CRL) for roluperidone in February 2024, requiring additional studies and data for approval; the company is actively engaging with the FDA to address these deficiencies.

• No products have been approved or commercialized, and no revenue has been generated from product sales.

• As of September 30, 2024, cash, cash equivalents, and restricted cash totaled $26.6 million, expected to fund operations for at least the next 12 months.

• The company focuses on CNS diseases, with lead candidate roluperidone for schizophrenia and MIN-301 for Parkinson's disease.

Financial highlights

• Q3 2024 R&D expense was $1.9 million, down from $3.4 million in Q3 2023; nine-month R&D expense increased to $9.9 million.

• Q3 2024 G&A expense was $2.5 million, slightly lower than $2.6 million in Q3 2023; nine-month G&A expense decreased to $7.4 million.

• Other income for Q3 2024 was $26.6 million, due to the royalty obligation adjustment.

• Cash used in operating activities was $14.4 million for the nine months ended September 30, 2024.

• Cash, cash equivalents, and restricted cash totaled $26.6 million at September 30, 2024.

Outlook and guidance

• Management expects continued operating losses and negative cash flows from operations as drug development progresses.

• Additional capital will be required to fund later-stage clinical development and potential commercialization; the company is exploring equity financings and other arrangements.

• Cash on hand is expected to meet operating commitments for at least the next 12 months.

• Future performance is subject to regulatory outcomes, ability to raise additional capital, and general economic conditions.